blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2888010

EP2888010 - METHODS FOR INHIBITING FASCIN [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.03.2022
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  16.04.2021
FormerGrant of patent is intended
Status updated on  16.12.2020
FormerExamination is in progress
Status updated on  28.10.2020
FormerGrant of patent is intended
Status updated on  17.06.2020
FormerExamination is in progress
Status updated on  13.07.2018
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Cornell University
Cornell Center for Technology, Enterprise
& Commercialization
395 Pine Tree Road, Suite 310
Ithaca, NY 14850 / US
For all designated states
Novita Pharmaceuticals, Inc.
1161 York Avenue 8C
New York, NY 10065 / US
[2020/29]
Former [2015/27]For all designated states
Cornell University
395 Pine Tree Road
Ithaca, NY 14850 / US
For all designated states
Novita Pharmaceuticals Inc.
1161 York Avenue 8C
New York, NY 10065 / US
Inventor(s)01 / HUANG, Xin-yun
1161 York Avenue
8C
New York, NY 10065 / US
02 / SHUE, Christy, Young
288 Alfred Avenue
Englewood Cliffs, NJ 07632 / US
 [2015/27]
Representative(s)Barker Brettell LLP
100 Hagley Road
Edgbaston
Birmingham B16 8QQ / GB
[2021/20]
Former [2015/27]Atkinson, Jennifer
Barker Brettell LLP
100 Hagley Road
Edgbaston
Birmingham B16 8QQ / GB
Application number, filing date13830441.521.08.2013
[2021/20]
WO2013US55965
Priority number, dateUS201261692177P22.08.2012         Original published format: US 201261692177 P
US201361778015P12.03.2013         Original published format: US 201361778015 P
[2015/27]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2014031732
Date:27.02.2014
Language:EN
[2014/09]
Type: A2 Application without search report 
No.:EP2888010
Date:01.07.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 27.02.2014 takes the place of the publication of the European patent application.
[2015/27]
Type: B1 Patent specification 
No.:EP2888010
Date:19.05.2021
Language:EN
[2021/20]
Search report(s)International search report - published on:US01.05.2014
(Supplementary) European search report - dispatched on:EP22.06.2016
ClassificationIPC:A61P35/00, A61P35/04, A61K31/428, A61K31/433, A61K31/522, C07D487/04
[2016/14]
CPC:
C07D487/04 (EP,US); A61K31/428 (EP,US); A61K31/433 (EP,US);
A61K31/522 (EP,US); A61P25/00 (EP); A61P25/28 (EP);
A61P29/00 (EP); A61P31/04 (EP); A61P31/12 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P35/04 (EP);
A61P9/00 (EP); A61P9/10 (EP); C07D249/12 (US);
C07D277/82 (US); C07D285/08 (US); C07D405/12 (US);
Y02A50/30 (EP) (-)
Former IPC [2015/27]A61P35/00, A61P35/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/27]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN ZUR FASCINHEMMUNG[2015/27]
English:METHODS FOR INHIBITING FASCIN[2015/27]
French:MÉTHODES D'INHIBITION DE LA FASCINE[2015/27]
Entry into regional phase27.02.2015National basic fee paid 
27.02.2015Search fee paid 
27.02.2015Designation fee(s) paid 
27.02.2015Examination fee paid 
Examination procedure27.02.2015Examination requested  [2015/27]
17.01.2017Amendment by applicant (claims and/or description)
16.07.2018Despatch of a communication from the examining division (Time limit: M06)
24.01.2019Reply to a communication from the examining division
12.04.2019Despatch of a communication from the examining division (Time limit: M06)
22.10.2019Reply to a communication from the examining division
18.06.2020Communication of intention to grant the patent
28.10.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
17.12.2020Communication of intention to grant the patent
07.04.2021Fee for grant paid
07.04.2021Fee for publishing/printing paid
07.04.2021Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.07.2018
Opposition(s)22.02.2022No opposition filed within time limit [2022/17]
Fees paidRenewal fee
25.08.2015Renewal fee patent year 03
30.08.2016Renewal fee patent year 04
14.08.2017Renewal fee patent year 05
10.08.2018Renewal fee patent year 06
15.08.2019Renewal fee patent year 07
28.08.2020Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.08.2013
AL19.05.2021
AT19.05.2021
CY19.05.2021
CZ19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
MK19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
LU21.08.2021
IS19.09.2021
PT20.09.2021
[2024/22]
Former [2023/30]HU21.08.2013
AL19.05.2021
AT19.05.2021
CY19.05.2021
CZ19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
LU21.08.2021
IS19.09.2021
PT20.09.2021
Former [2023/29]HU21.08.2013
AL19.05.2021
AT19.05.2021
CZ19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
LU21.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/29]AL19.05.2021
AT19.05.2021
CZ19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
LU21.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/26]AL19.05.2021
AT19.05.2021
CZ19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
LU21.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/23]AT19.05.2021
CZ19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
LU21.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/18]AT19.05.2021
CZ19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
PT20.09.2021
IS22.12.2021
Former [2022/10]AT19.05.2021
CZ19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
PT20.09.2021
IS22.12.2021
Former [2022/09]AT19.05.2021
CZ19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/07]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
PL19.05.2021
RS19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2021/52]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
PL19.05.2021
RS19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2021/51]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
RS19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2021/50]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
PT20.09.2021
Former [2021/49]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
Former [2021/47]AT19.05.2021
FI19.05.2021
LT19.05.2021
BG19.08.2021
Former [2021/46]AT19.05.2021
FI19.05.2021
LT19.05.2021
Documents cited:Search[X]WO0024725  (VERTEX PHARMA [US], et al) [X] 1,9-13 * p. 1, first §; table I *;
 [X]WO03040117  (ORTHO MCNEIL PHARMACEUTICAL CO [US]) [X] 1,9-13 * compounds of table 2, e.g. compound 82; compounds of table I, in particular c. 2, 6-8, 11-15, 22; example 9 *;
 [X]US2004009613  (ZHOU MING-MING [US], et al) [X] 1,12,13 * compound of Fig. 13-11, col. 3, row 4; claims 14-20 *;
 [X]WO2005037845  (RIGEL PHARMACEUTICALS INC [US], et al) [X] 1,12-15 * claims 26-28; compounds of table 1, in particular compounds 47, 48 at p. 34; compound 184 at p. 27 *;
 [X]WO2005040114  (OXAGEN LTD [GB], et al) [X] 1,5,8,13 * claims 16, 20-21 *;
 [X]US2005187268  (VON RECHENBERG MORITZ [US], et al) [X] 1,9-13 * §0142; §0029 *;
 [X]WO2006047162  (BURNHAM INST [US], et al) [X] 1,9-13 * claims, e.g. claim 19; table I, compound 5858065;example 1, §0092 *;
 [X]WO2008057862  (BRISTOL MYERS SQUIBB CO [US], et al) [X] 1,12,13 * compounds 137, 138 at p. 112; compounds 126, 127 at p. 111; compounds 50 and 57 at p. 106; compounds 45 and 47 at p. 105, compound 38-39 *;
 [X]WO2008129276  (BOEHRINGER INGELHEIM INT [DE], et al) [X] 1,4,5,7,8,13 * examples 1-3, 5-10, 18-21, 23, 25; claims 27-28 *;
 [X]WO2010033986  (UNIV MINNESOTA [US], et al) [X] 1,9-13 * p. 38, second compound; p. 21, l. 1-4 *;
 [X]WO2011006158  (UNIV MARYLAND [US], et al) [X] 1,12,13 * p. 91, compound 140; p. 1, middle *;
 [X]WO2011133862  (UNIV OREGON HEALTH & SCIENCE [US], et al) [X] 1,8,13 * compound of p. 19; claim 9 *;
 [X]EP2484670  (CONSEJO SUPERIOR INVESTIGACION [ES]) [X] 1,9-13* p. 15, table I, first and second compound and p. 16, l. 16 *;
 [X]  - VALLE PALOMO ET AL, "5-Imino-1,2,4-Thiadiazoles: First Small Molecules As Substrate Competitive Inhibitors of Glycogen Synthase Kinase 3", JOURNAL OF MEDICINAL CHEMISTRY, (20120223), vol. 55, no. 4, doi:10.1021/jm201463v, ISSN 0022-2623, pages 1645 - 1661, XP055061236 [X] 1,10,11,13 * title, abstract; compounds of table 2, e.g. compounds 31, 33, 44, 56 *

DOI:   http://dx.doi.org/10.1021/jm201463v
International search[Y]US2005209252  (TENG CHE-MING [TW], et al);
 [Y]WO2009070244  (UNIV CORNELL [US], et al);
 [Y]US2011201609  (LAWRENCE HARSHANI [US], et al)
ExaminationUS4786644
by applicantUS4559157
 US4608392
 US4820508
 US4938949
 US4992478
 US5846514
 US6334997
 WO2009070244
    - DEAN, D., "Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development", Curr. Pharm. Des., (20000000), vol. 6, no. 10
    - KABALKA, G. et al., "The Synthesis of Radiolabeled Compounds via Organometallic Intermediates", Tetrahedron, (19890000), vol. 45, no. 21, pages 6601 - 21
    - EVANS, E., "Synthesis of radiolabeled compounds", J. Radioanal. Chem., (19810000), vol. 64, no. 1-2, pages 9 - 32
    - KRAFT et al., "Phenotypes of Drosophila brain neurons in primary culture reveal a role for fascin in neurite shape and trajectory", J. Neurosci, (20060000), vol. 26, no. 34, pages 8734 - 47
    - FULGA et al., "Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo", Nat Cell Biol, (20070000), vol. 9, no. 2, doi:doi:10.1038/ncb1528, pages 139 - 48, XP055190554

DOI:   http://dx.doi.org/10.1038/ncb1528
    - PINKUS et al., "Fascin, a sensitive new marker for Reed-Sternberg cells of Hodgkin's disease", Am J Pathol, (19970000), vol. 150, no. 2, pages 543 - 562
    - MOSIALOS et al., "Circulating human dendritic cells differentially express high levels of a 55-kd actin-bundling protein", Am. J. Pathol., (19960000), vol. 148, no. 2, pages 593 - 600
    - SAID et al., "The role of follicular and inter digitating dendritic cells in HIV-related lymphoid hyperplasia: localization of fascin", Mod Pathol, (19970000), vol. 10, no. 5, pages 421 - 27
    - MELLER et al., "Ubiquitin proteasome-mediated synaptic reorganization: a novel mechanism underlying rapid ischemic tolerance", J Neurosci, (20080000), vol. 28, no. 1, pages 50 - 9
    - KRAFT et al., J. Neurosci., (20060823), vol. 26, no. 34, pages 8734 - 47
    - PINKUS et al., Am J Pathol, (19970200), vol. 150, no. 2, pages 543 - 62
    - MOSIALOS et al., Am J Pathol, (19960200), vol. 148, no. 2, pages 593 - 600
    - FULGA et al., Nat Cell Biol, (20070200), vol. 9, no. 2, pages 139 - 48
    - SAID et al., Mod Pathol, (19970500), vol. 10, no. 5, pages 421 - 7
    - MELLER et al., J Neurosci, (20080102), vol. 28, no. l, pages 50 - 9
    - FIESER; FIESER, Reagentsfor Organic Synthesis, John Wiley and Sons, (19910000), vol. 1-15
    - RODD, Chemistry of Carbon Compounds, Elsevier Science Publishers, (19890000), vol. 1-5
    - Organic Reactions, John Wiley and Sons, (19910000), vol. 1-40
    - MARCH, Advanced Organic Chemistry, John Wiley and Sons
    - ANNA ROGLANS et al., "Diazonium Salts as Substrates in Palladium-Catalyzed Cross-Coupling Reactions", Chem. Rev., (20060000), vol. 106, no. 11, pages 4622 - 4643
    - BRAD M. ROSEN et al., "Nickel-Catalyzed Cross-Couplings Involving Carbon-Oxygen Bonds", Percec Chem. Rev., (20110000), vol. 111, no. 3, pages 1346 - 1416
    - JEAN-PIERRE CORBET et al., "Selected Patented Cross-Coupling Reaction Technologies", Chem. Rev., (20060000), vol. 106, no. 7, doi:doi:10.1021/cr0505268, pages 2651 - 2710, XP055394135

DOI:   http://dx.doi.org/10.1021/cr0505268
    - GWILHERM EVANO et al., "Copper-Mediated Coupling Reactions and Their Applications in Natural Products and Designed Biomolecules Synthesis", Chem. Rev., (20080000), vol. 108, no. 8, doi:doi:10.1021/cr8002505, pages 3054 - 3131, XP008151521

DOI:   http://dx.doi.org/10.1021/cr8002505
    - BENNY BOGOSLAVSKY et al., "Formation of a Carbon-Carbon Triple Bond by Coupling Reactions In Aqueous Solution", Science, (20050000), vol. 308, no. 5719, pages 234 - 235
    - M. LAFRANCE et al., "Catalytic Intermolecular Direct Arylation of Perfluorobenzenes", J. Am. Chem. Soc., (20060000), vol. 128, no. 27, pages 8754 - 8756
    - NORIO MIYAURA et al., "A new stereospecific cross-coupling by the palladium-catalyzed reaction of 1-alkenylboranes with 1-alkenyl or 1-alkynyl halides", Tetrahedron Letters, (19790000), vol. 20, no. 36, pages 3437 - 3440
    - P.E. FANTA, "The Ullmann Synthesis of Biaryls", Synthesis, (19740000), vol. 1974, pages 9 - 21
    - M. GOMBERG; W. E. BACHMANN, J. Am. Chem. Soc., (19240000), vol. 42, no. 10, pages 2339 - 2343
    - R. J. P. CORRIU; MASSE, J. P., "Activation of Grignard reagents by transition-metal complexes. A new and simple synthesis of trans-stilbenes and polyphenyls", Journal of the Chemical Society, Chemical Communications, (19720000), page 144a
    - SHAN, D. et al., "Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice", Proc. Nat. Acad. Sci., (20050000), vol. 102, doi:doi:10.1073/pnas.0500658102, pages 3772 - 3776, XP002356046

DOI:   http://dx.doi.org/10.1073/pnas.0500658102
    - HANAHAN, D.; WEINBERG, R. A., "The hallmarks of cancer", Cell, (20000000), vol. 100, pages 57 - 70, XP055447752
    - CHRISTOFORI, G., "New signals from the invasive front", Nature, (20060000), vol. 441, doi:doi:10.1038/nature04872, pages 444 - 450, XP002484498

DOI:   http://dx.doi.org/10.1038/nature04872
    - WEISS, L., "Metastasis of cancer: a conceptual history from antiquity to the 1990s", Cancer Metastasis Rev, (20000000), vol. 19, no. I-XI, pages 193 - 383
    - FIDLER, I. J., "The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited", Nat Rev Cancer, (20030000), vol. 3, pages 453 - 458
    - VALASTYAN, S.; WEINBERG, R. A., "Tumor metastasis: molecular insights and evolving paradigms", Cell, (20110000), vol. 147, doi:doi:10.1016/j.cell.2011.09.024, pages 275 - 292, XP028317884

DOI:   http://dx.doi.org/10.1016/j.cell.2011.09.024
    - FORNIER, M. N., "Approved agents for metastatic breast cancer", Semin Oncol, (20110000), vol. 38, no. 2, pages 3 - 10
    - DAVIES, J. M.; GOLDBERG, R. M., "Treatment of metastatic colorectal cancer", Semin Oncol, (20110000), vol. 38, pages 552 - 560
    - SONDAK, V. K.; HAN, D.; DENEVE, J.; KUDCHADKAR, R., "Current and planned multicenter trials for patients with primary or metastatic melanoma", J Surg Oncol, (20110000), vol. 104, pages 430 - 437
    - PARTIN, A. W.; SCHOENIGER, J. S.; MOHLER, J. L.; COFFEY, D. S., "Fourier analysis of cell motility: correlation of motility with metastatic potential", Proc Natl AcadSci USA, (19890000), vol. 86, pages 1254 - 1258
    - AZNAVOORIAN, S.; MURPHY, A. N.; STETLER-STEVENSON, W. G.; LIOTTA, L. A., "Molecular aspects of tumor cell invasion and metastasis", Cancer, (19930000), vol. 71, pages 1368 - 1383
    - CONDEELIS, J.; SINGER, R. H.; SEGALL, J. E., "The great escape: when cancer cells hijack the genes for chemotaxis and motility", Annu Rev Cell Dev Biol, (20050000), vol. 21, pages 695 - 718
    - ROUSSOS, E. T.; CONDEELIS, J. S.; PATSIALOU, A., "Chemotaxis in cancer", Nat Rev Cancer, (20110000), vol. 11, pages 573 - 587
    - JAFFE, A. B.; HALL, A., "Rho GTPases: biochemistry and biology", Annu Rev Cell Dev Biol, (20050000), vol. 21, pages 247 - 269
    - MATSUDAIRA, P., "Actin crosslinking proteins at the leading edge", Semin Cell Biol, (19940000), vol. 5, doi:doi:10.1006/scel.1994.1021, pages 165 - 174, XP024800084

DOI:   http://dx.doi.org/10.1006/scel.1994.1021
    - OTTO, J. J., "Actin-bundling proteins", Curr Opin Cell Biol, (19940000), vol. 6, doi:doi:10.1016/0955-0674(94)90123-6, pages 105 - 109, XP025588259

DOI:   http://dx.doi.org/10.1016/0955-0674(94)90123-6
    - MOGILNER, A.; RUBINSTEIN, B., "The physics of filopodial protrusion", Biophys J, (20050000), vol. 89, pages 782 - 795
    - MATTILA, P. K.; LAPPALAINEN, P., "Filopodia: molecular architecture and cellular functions", Nat Rev Mol Cell Biol, (20080000), vol. 9, pages 446 - 454
    - OTTO, J. J.; KANE, R. E.; BRYAN, J., "Formation of filopodia in coelomocytes: localization of fascin, a 58,000 dalton actin cross-linking protein", Cell, (19790000), vol. 17, doi:doi:10.1016/0092-8674(79)90154-5, pages 285 - 293, XP023909413

DOI:   http://dx.doi.org/10.1016/0092-8674(79)90154-5
    - BRYAN, J.; KANE, R. E., "Separation and interaction of the major components of sea urchin actin gel", J Mol Biol, (19780000), vol. 125, doi:doi:10.1016/0022-2836(78)90345-5, pages 207 - 224, XP024013556

DOI:   http://dx.doi.org/10.1016/0022-2836(78)90345-5
    - YAMASHIRO-MATSUMURA, S.; MATSUMURA, F., "Purification and characterization of an F-actin-bundling 55-kilodalton protein from HeLa cells", JBiol Chem, (19850000), vol. 260, pages 5087 - 5097
    - VIGNJEVIC, D.; YARAR, D.; WELCH, M. D.; PELOQUIN, J.; SVITKINA, T.; BORISY, G. G., "Formation of filopodia-like bundles in vitro from a dendritic network", J Cell Biol, (20030000), vol. 160, pages 951 - 962
    - VIGNJEVIC, D.; KOJIMA, S.; ARATYN, Y.; DANCIU, O.; SVITKINA, T.; BORISY, G. G., "Role of fascin in filopodial protrusion", J Cell Biol, (20060000), vol. 174, doi:doi:10.1083/jcb.200603013, pages 863 - 875, XP055018209

DOI:   http://dx.doi.org/10.1083/jcb.200603013
    - ADAMS, J. C., "Roles of fascin in cell adhesion and motility", Curr Opin Cell Biol, (20040000), vol. 16, doi:doi:10.1016/j.ceb.2004.07.009, pages 590 - 596, XP004567200

DOI:   http://dx.doi.org/10.1016/j.ceb.2004.07.009
    - TILNEY, L. G.; CONNELLY, P. S.; VRANICH, K. A.; SHAW, M. K.; GUILD, G. M., "Why are two different cross-linkers necessary for actin bundle formation in vivo and what does each cross-link contribute?", J Cell Biol, (19980000), vol. 143, pages 121 - 133
    - DARNEL, A. D.; BEHMOARAM, E.; VOLLMER, R. T.; CORCOS, J.; BIJIAN, K.; SIRCAR, K.; SU, J.; JIAO, J.; ALAOUI-JAMALI, M. A.; BISMAR,, "Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer", Clin Cancer Res, (20090000), vol. I5, pages 1376 - 1383
    - PELOSI, G.; PASINI, F.; FRAGGETTA, F.; PASTORINO, U.; IANNUCCI, A.; MAISONNEUVE, P.; ARRIGONI, G.; DE MANZONI, G.; BRESAOLA, E.; V, "Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids", Lung Cancer, (20030000), vol. 42, pages 203 - 213
    - HASHIMOTO, Y.; SHIMADA, Y.; KAWAMURA, J.; YAMASAKI, S.; IMAMURA, M., "The prognostic relevance of fascin expression in human gastric carcinoma", Oncology, (20040000), vol. 67, pages 262 - 270
    - CAO, D.; JI, H.; RONNETT, B. M., "Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary", Int J Gynecol Pathol, (20050000), vol. 24, pages 67 - 72, XP009105317
    - RODRIGUEZ-PINILLA, S. M.; SARRIO, D.; HONRADO, E.; HARDISSON, D.; CALERO, F.; BENITEZ, J.; PALACIOS, J., "Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas", Clin Cancer Res, (20060000), vol. 12, pages 1533 - 1539
    - GROTHEY, A.; HASHIZUME, R.; SAHIN, A. A.; MCCREA, P. D., "Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer", Br J Cancer, (20000000), vol. 83, pages 870 - 873
    - HASHIMOTO, Y.; SKACEL, M.; ADAMS, J. C., "Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?", Int J Biochem Cell Biol, (20050000), vol. 37, doi:doi:10.1016/j.biocel.2005.05.004, pages 1787 - 1804, XP004974392

DOI:   http://dx.doi.org/10.1016/j.biocel.2005.05.004
    - MAITRA, A.; IACOBUZIO-DONAHUE, C.; RAHMAN, A.; SOHN, T. A.; ARGANI, P.; MEYER, R.; YEO, C. J.; CAMERON, J. L.; GOGGINS, M.; KERN,, "Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homo log and heat shock protein 47", Am J Clin Pathol, (20020000), vol. 118, pages 52 - 59
    - YODER, B. J.; TSO, E.; SKACEL, M.; PETTAY, J.; TARR, S.; BUDD, T.; TUBBS, R. R.; ADAMS, J. C.; HICKS, D. G., "The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course", Clin Cancer Res, (20050000), vol. 11, pages 186 - 192
    - ZIGEUNER, R.; DROSCHL, N.; TAUBER, V.; REHAK, P.; LANGNER, C., "Biologic significance of fascin expression in clear cell renal cell carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique", Urology, (20060000), vol. 68, doi:doi:10.1016/j.urology.2006.03.032, pages 518 - 522, XP025075832

DOI:   http://dx.doi.org/10.1016/j.urology.2006.03.032
 US19770616921
 US20150617780
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.